ESMO 2022 Conference Coverage
ESMO 2022 on the Phase 1 Study of PRL-02, a Long-Acting IM Depot Injection of Abiraterone Decanoate in Patients With Prostate Cancer
By
ESMO 2022 Conference Coverage
FEATURING
Jose Avitia
By
ESMO 2022 Conference Coverage
FEATURING
Jose Avitia
Comments 0
Login to view comments.
Click here to Login